Gene Therapy Yields Improvements in AADC-Deficiency: Paul Wuh-Liang Hwu, MD, PhD


The professor from National Taiwan University Hospital discussed 3 studies of PTC-AADC for AADC deficiency.

"Those patients [with AADC deficiency], especially with a classic type or severe type of the disease, have no available effective medical treatments. So, we started treating patients with gene therapy here and they have a chance to become better and to have improvements in their disease.”

Updated data from a 5-year analysis of 3 clinical trials announced by PTC Therapeutics demonstrate that treatment with the novel gene therapy PTC-AADC leads to durable developmental, motor, and cognitive improvements in children with aromatic L-Amino acid decarboxylase (AADC) deficiency.1,2

The data were presented at the 50th Child Neurology Society (CNS) Annual Meeting, September 29 to October 2. Treated children reached milestones such as holding up their heads and sitting or standing with support as early as 3 months after treatment. Children also had improved communication skills via Bayley-3 scores.

GeneTherapyLive spoke with investigator Paul Wuh-Liang Hwu, MD, PhD, professor, pediatrics, National Taiwan University Hospital, to learn more about the studies included in the analysis, and he provided an overview of some of the improvements seen in patients with AADC deficiency treated with PTC-AADC.

1. Results show long-lasting and holistic improvements in children with AADC deficiency treated with PTC-AADC gene therapy. News release. PTC Therapeutics. September 29, 2021.
2. Hwu PWL, Kiening K, Anselm I, et al. Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Mol Med. 2021;13:e14712. doi: 10.15252/emmm.202114712
Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.